CSIMarket
 
Bioxcel Therapeutics Inc   (BTAI)
Other Ticker:  
 
 
Price: $2.6800 $-0.19 -6.620%
Day's High: $2.88 Week Perf: -7.59 %
Day's Low: $ 2.58 30 Day Perf: -13.55 %
Volume (M): 1,456 52 Wk High: $ 29.56
Volume (M$): $ 3,903 52 Wk Avg: $8.99
Open: $2.82 52 Wk Low: $1.91



 Market Capitalization (Millions $) 78
 Shares Outstanding (Millions) 29
 Employees 51
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -212
 Cash Flow (TTM) (Millions $) -142
 Capital Exp. (TTM) (Millions $) 0

Bioxcel Therapeutics Inc
Bioxcel Therapeutics Inc. is a clinical-stage biopharmaceutical company that uses artificial intelligence (AI) and machine learning (ML) to identify potential neurological and immuno-oncological therapies. The company was founded in 2017 and is headquartered in New Haven, Connecticut, with additional offices in San Francisco, California, and Noida, India.

The company's AI-based approach involves analyzing large data sets of genetic, clinical, and pharmacological information to identify potential drug candidates for specific diseases. The platform uses algorithms to predict the efficacy of the drug candidate, potential side effects, and patient selection criteria for clinical trials.

Bioxcel's lead drug candidate, BXCL501, is a sublingual thin film formulation of dexmedetomidine that is being developed for the treatment of agitation in patients with schizophrenia and bipolar disorder. The drug has shown promising results in Phase 1b/2 clinical trials, with significant reductions in agitation and anxiety in patients.

The company's second drug candidate, BXCL701, is a small molecule immune activator being developed for the treatment of various types of cancer. The drug has shown potential in preclinical studies to enhance the immune system's ability to recognize and attack cancer cells.

Bioxcel has also partnered with leading pharmaceutical companies such as Pfizer and Urovant Sciences to develop and commercialize its pipeline of neurology and oncology drugs.

In addition to its drug development efforts, Bioxcel is also focused on building a data-driven approach to patient identification and recruitment for clinical trials. The company is using its AI platform to identify patient populations that are most likely to benefit from its therapies and to optimize clinical trial design and execution.

Overall, Bioxcel Therapeutics is a biopharmaceutical company that is leveraging AI and ML to develop innovative therapies for neurological and immuno-oncological diseases. The company's unique approach to drug development and patient identification has the potential to significantly improve patient outcomes and accelerate the drug development process.


   Company Address: 555 Long Wharf Drive New Haven 6511 CT
   Company Phone Number: 238-6837   Stock Exchange / Ticker: NASDAQ BTAI
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

BioXcel Therapeutics Grapples with Roadblocks as Plans for Public Offering are Scrapped

Published Tue, Feb 13 2024 2:01 PM UTC



In a recent press release, BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a pioneering biopharmaceutical company specializing in neuroscience and immuno-oncology, shocked the industry by announcing the termination of its proposed public offering. This decision comes in the wake of significant financial setbacks, including a cumulative net loss of $212 million in the th...

Clinical Study

Significant Milestone in Pancreatic Cancer Treatment: Completion of Patient Enrollment for Phase 2 Trial Involving the BXCL701-KEYTRUDA Combo

Published Tue, Feb 6 2024 12:00 PM UTC

BioXcel Therapeutics, a clinical-stage biopharmaceutical company, has achieved an important milestone in its investigator-sponsored Phase 2 relapsed pancreatic cancer trial. The firm announced the completion of patient enrollment in a critical safety portion of the study, proposing a potential new treatment option for an aggressive form of cancer. The therapy trial involves ...

Bioxcel Therapeutics Inc

Bioxcel Therapeutics Inc: Surging Revenue Brings Growth But Fails to Yield Profitability

Bioxcel Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative therapies for patients with serious diseases and unmet medical needs. The company recently announced a significant revenue advance of 148.905% year on year, reaching $0.34 million in the most recent fiscal period. While this demonstrates strong growth for the company, it is important to note that losses have also expanded, with a reported loss of $-1.72 million from the previous quarter.
In terms of earnings per share (EPS), there has been an improvement from $-1.83 per share in the previous quarter to the current period's results. However, revenue has fallen by -25.383%, going from $0.46 million to the current reported amount. These figures highlight some volatility in Bioxcel Therapeutics Inc's financial performance.

Bioxcel Therapeutics Inc

Bioxcel Therapeutics Inc Reports $0.457 Million Revenue Decline in Q2 2023, Net Deficit Soars to $-53.515 Million



Bioxcel Therapeutics Inc recently released its financial results for the fiscal period closing on June 30, 2023. The company reported a revenue of $0.457 million, indicating a decrease compared to the previous quarter. However, the net deficit expanded to $-53.515 million, highlighting a significant increase from the previous year. Additionally, the company's inventories decreased to $1.9 million due to the seasonal nature of its business. This article will provide an overview of the financial results and assess the implications for Bioxcel Therapeutics Inc.
Financial Results:
Bioxcel Therapeutics Inc's revenue for the fiscal period ending June 30, 2023, was $0.457 million, representing a decline in comparison to the previous quarter. This decrease in revenue may be attributed to various factors, such as market conditions and business strategy adjustments. It is important to note that revenues from this fiscal period also increased compared to the same period a year ago.

Bioxcel Therapeutics Inc

Bioxcel Therapeutics Inc Generates Impressive $0.206 Million in Revenue, on Track for Strong 2023

As a financial journalist, I have analyzed the latest results of the major pharmaceutical preparations company, which reported an impressive revenue of $0.206 million in the first quarter of 2023. This indicates that the company is on track to achieve its financial targets for the year.
However, my attention was drawn to the concerning financial figures revealed by Bioxcel Therapeutics Inc, which indicates a net deficit of $-52.796 million in the first quarter of 2023, a significant increase from the $-31.472 million reported a year ago. This shows that the company is currently experiencing financial difficulties, which may impact its operations and business growth.






 

Bioxcel Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com